NASDAQ:HOOK

Hookipa Pharma - HOOK Stock Forecast, Price & News

$1.34

-0.12 (-8.22%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.31
▼
$1.48
50-Day Range: $1.27
▼
$1.73
52-Week Range: $1.23
▼
$6.05

Volume: 324,325 shs
Average Volume: 161,569 shs
Market Capitalization: $73.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Hookipa Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 497.0% Upside
$8.00 Price Target
Short Interest: Healthy
1.83% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.97
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.29) to ($1.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

372nd out of 1,093 stocks

Pharmaceutical Preparations Industry

166th out of 547 stocks

3.4

Analyst's Opinion

Consensus Rating
Hookipa Pharma has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Hookipa Pharma has a forecasted upside of 497.0% from its current price of $1.34.
Amount of Analyst Coverage
Hookipa Pharma has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.83% of the outstanding shares of Hookipa Pharma have been sold short.
Short Interest Ratio / Days to Cover
Hookipa Pharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Hookipa Pharma has recently decreased by 3.85%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Hookipa Pharma does not currently pay a dividend.
Dividend Growth
Hookipa Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOOK.

3.3

News and Social Media Coverage

News Sentiment
Hookipa Pharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Hookipa Pharma this week, compared to 1 article on an average week.
Search Interest
6 people have searched for HOOK on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hookipa Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Hookipa Pharma is held by insiders.
Percentage Held by Institutions
53.98% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Hookipa Pharma are expected to grow in the coming year, from ($1.29) to ($1.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hookipa Pharma is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hookipa Pharma is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hookipa Pharma has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Hookipa Pharma (NASDAQ:HOOK) Stock

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Stock News Headlines

September 30, 2022 | americanbankingnews.com

Hookipa Pharma Inc (NASDAQ:HOOK) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 29, 2022 | finance.yahoo.com

HOOKIPA Pharma Inc. (HOOK) Upgraded to Buy: What Does It Mean for the Stock?

September 27, 2022 | finance.yahoo.com

Investors in HOOKIPA Pharma (NASDAQ:HOOK) have unfortunately lost 81% over the last three years

September 5, 2022 | seekingalpha.com

Aquestive Therapeutics: FDA Stymies Libervant Launch

August 19, 2022 | seekingalpha.com

HOOKIPA Pharma (HOOK) August-2022-Investor-Presentation

August 4, 2022 | finance.yahoo.com

HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022

July 25, 2022 | msn.com

HOOKIPA Gets FDA Nod For Initial-Stage Prostate Cancer Study

July 25, 2022 | finance.yahoo.com

FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer

July 25, 2022 | finance.yahoo.com

FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer

July 8, 2022 | finance.yahoo.com

What Is The Ownership Structure Like For HOOKIPA Pharma Inc. (NASDAQ:HOOK)?

June 21, 2022 | finance.yahoo.com

HOOKIPA Announces Executive Leadership Changes

June 9, 2022 | finance.yahoo.com

HOOKIPA to Participate in the JMP Securities Life Sciences Conference

June 5, 2022 | finance.yahoo.com

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

June 3, 2022 | seekingalpha.com

Hookipa posts positive preclinical data from arenaviral HIV therapeutic vaccines trial

June 3, 2022 | finance.yahoo.com

Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium

May 26, 2022 | tmcnet.com

HOOKIPA to Present Complete HB-200 Phase 1

May 26, 2022 | finance.yahoo.com

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

May 18, 2022 | finance.yahoo.com

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 16, 2022 | finance.yahoo.com

HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates

May 16, 2022 | investing.com

HOOKIPA Pharma Inc. Reports Q1 Net Loss of $18M

May 16, 2022 | benzinga.com

Recap: HOOKIPA Pharma Q1 Earnings

May 16, 2022 | finance.yahoo.com

HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights

May 13, 2022 | finance.yahoo.com

CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates

May 9, 2022 | finance.yahoo.com

HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022

May 2, 2022 | seekingalpha.com

HOOKIPA Pharma promotes business chief to COO role

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Company Calendar

Last Earnings: 11/12/2021
Today: 10/01/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HOOK
CUSIP: N/A
CIK: 1760542
Web: www.hookipapharma.com
Phone: 431-890-6360
Fax: 43-1890-636-0399
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +497.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-75,660,000.00
Net Margins: -632.09%
Pretax Margin: -632.07%
Return on Equity: -63.32%
Return on Assets: -47.53%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 5.48
Quick Ratio: 5.48

Sales & Book Value

Annual Sales: $18.45 million
Price / Sales: 3.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.87 per share
Price / Book: 0.47

Miscellaneous

Outstanding Shares: 54,710,000
Free Float: 52,189,000
Market Cap: $73.31 million
Optionable: Not Optionable
Beta: 0.77

Key Executives

Mr. Joern Aldag (Age 60)
Pres, CEO & Director

Mr. Daniel Pinschewer (Age 44)
Founder & Chief Scientific Officer

Dr. Reinhard Kandera (Age 50)
CFO & Director

Mr. Anders Lilja Ph.D. (Age 46)
Sr. VP of Technical Devel.

Mrs. Nina Waibel
Communications & Investor Relations Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HOOK Stock - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings or view top-rated stocks.
What is Hookipa Pharma's stock price forecast for 2022?: 7 equities research analysts have issued 1 year target prices for Hookipa Pharma's shares. Their HOOK share price forecasts range from $3.00 to $11.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 497.0% from the stock's current price.
View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts.
How have HOOK shares performed in 2022?: Hookipa Pharma's stock was trading at $2.33 at the start of the year. Since then, HOOK stock has decreased by 42.5% and is now trading at $1.34.
View the best growth stocks for 2022 here.
When is Hookipa Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our HOOK earnings forecast.
How were Hookipa Pharma's earnings last quarter?: Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.09. The firm had revenue of $3.87 million for the quarter, compared to the consensus estimate of $5.24 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 63.32% and a negative net margin of 632.09%. During the same period in the previous year, the company posted ($0.53) EPS.

What other stocks do shareholders of Hookipa Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX).
When did Hookipa Pharma IPO?: (HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.
What is Hookipa Pharma's stock symbol?: Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."
How do I buy shares of Hookipa Pharma?: Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Hookipa Pharma's stock price today?: One share of HOOK stock can currently be purchased for approximately $1.34.
How much money does Hookipa Pharma make?: Hookipa Pharma (NASDAQ:HOOK) has a market capitalization of $73.31 million and generates $18.45 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.
How can I contact Hookipa Pharma?: Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The official website for the company is www.hookipapharma.com. The company can be reached via phone at 431-890-6360, via email at ir@hookipapharma.com, or via fax at 43-1890-636-0399.

This page (NASDAQ:HOOK) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hookipa Pharma - HOOK Stock Forecast, Price & News

Hookipa Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month